Adlai Nortye Ltd. (NASDAQ:ANL - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings estimates for Adlai Nortye in a research report issued to clients and investors on Tuesday, April 23rd. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($2.41) for the year, up from their prior estimate of ($2.50). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Adlai Nortye's current full-year earnings is ($2.90) per share.
Adlai Nortye Price Performance
NASDAQ:ANL traded down $0.09 during trading hours on Thursday, hitting $13.46. 4,531 shares of the stock traded hands, compared to its average volume of 7,096. Adlai Nortye has a 1 year low of $7.11 and a 1 year high of $19.30. The stock has a 50 day moving average price of $9.21 and a 200 day moving average price of $9.28.
Hedge Funds Weigh In On Adlai Nortye
An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its stake in shares of Adlai Nortye Ltd. (NASDAQ:ANL - Free Report) by 128.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 40,310 shares of the company's stock after acquiring an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 at the end of the most recent quarter. Institutional investors and hedge funds own 35.21% of the company's stock.
Adlai Nortye Company Profile
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Recommended Stories
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
